**Abstract**

***Objectives:*** Despite its clinical utility, a pharmacogenetic test for response to the antipsychotic clozapine has yet to be developed. Thus, we sought to create a preliminary genetic model for response. Multiple genetic variants from different systems (e.g. dopamine, serotonin) have been linked with clozapine response. Previous work by our group has implicated multiple dopamine D2 receptor (*DRD2*) genetic variants, including the genome-wide significant schizophrenia risk variant rs2514218. Thus, we focused our model on dopamine system-related gene variants.

***Methods:*** We analyzed genetic variants in dopamine system-related genes in relation to clozapine response. The sample consisted of 151 Caucasian schizophrenia (DSM-III) patients treated with clozapine for six months. Response was assessed using the Brief Psychiatric Rating Scale (BPRS), and evaluated based upon absolute score change and binary response (Kane et al. 1988 criteria). Variants showing at least a nominal statistical trend (p\>0.1) were included in the model. The mode of inheritance of all single nucleotide polymorphisms (SNPs) was determined and risk scores for each SNP calculated using standard procedures.

***Results:*** Five SNPs were included in the model: *DRD2* rs2514218, rs1799978 and rs2242531, *COMT* rs4680, and *BDNF* rs6265. We observed a significant association between total risk score with BPRS score change (*p*=0.029, Adjusted R^2^=0.41) and binary response (*p*=0.013, Nagelkerke R^2^=0.30). Individuals with the lowest risk score experienced the smallest decrease in BPRS score.

***Conclusions:*** We have developed a preliminary genetic model for clozapine response, and are currently assembling a replication sample for further testing. The fact that a model based upon dopamine system genetic variants may explain variation in clozapine response indicates that the drug's therapeutic effect depends in part on its effects on dopaminergic activity in multiple brain regions. These include direct effects on D1 and D4 receptors, and indirect ones through activity at 5-HT2A and 5-HT1A receptors.
